Journals / MN Oftalmoloji / 2018 / Cilt: 25 - Sayı: 0

Adenoviral Keratoconjunctivitis: Case Presentations and Review of Literature

Adenoviral Keratokonjonktivit: Olgu Sunumları ile Derleme

Pages
45–52
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The use of topical 2% cyclosporine A in the early phase of AAK may decrease the severity and duration of symptoms, has an inhibitory effect on the development of corneal subepithelial infiltrates, and has the advantage of being a steroid-sparing agent.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute adenoviral keratoconjunctivitis is the most common external ocular viral infection worldwide.
📊
Key Findings & Data:It is highly contagious and, different from other forms of viral conjunctivitis, corneal involvement and visual impairment may occur.
💡
Conclusion & Impact:The use of topical 2% cyclosporine A in the early phase of AAK may decrease the severity and duration of symptoms, has an inhibitory effect on the development of corneal subepithelial infiltrates, and has the advantage of being a steroid-sparing agent.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Acute adenoviral keratoconjunctivitis is the most common external ocular viral infection worldwide. It is highly contagious and, different from other forms of viral conjunctivitis, corneal involvement and visual impairment may occur. The aim of treatment in AAK is to alleviate the symptoms. Cold compresses, topical antihistamines and artificial tears are recomended for this purpose. However, there is no proven effective treatment up to date. The use of topical 2% cyclosporine A in the early phase of AAK may decrease the severity and duration of symptoms, has an inhibitory effect on the development of corneal subepithelial infiltrates, and has the advantage of being a steroid-sparing agent.

Özet

Akut adenoviral keratokonjonktivit, tüm dünyada en sık karşılaşılan eksternal oküler viral enfeksiyondur. Yüksek bulaşıcılığa sahiptir ve diğer viral konjonktivitlerden farklı olarak, kornea tutulumuna ve görme bozukluğuna yol açabilmektedir. Tedavide birincil amaç semptomların giderilmesidir. Bunun için soğuk uygulama, topikal antihistaminikler ve suni gözyaşı takviyesi önerilmektedir. Ancak günümüzde kornea tutulumunun ve hasta morbiditesinin önlenebilmesi için, etkinliği kanıt- lanmış bir tedavi yöntemi bulunmamaktadır. Hastalığın erken döneminde topikal %2 siklosporin A kullanımı ile belirtiler da- ha kısa süreli ve hafif olarak meydana gelmekte ve korneal subepitelyal infiltrat gelişim sıklığı azaltılabilmektedir. En önemli avantajı ise topikal steroid kullanımına alternatif bir ajan olmasıdır.

🔖

Cite This Article

ASENA, L., ALTINÖRS, D. D. (2018). Adenoviral Keratoconjunctivitis: Case Presentations and Review of Literature. MN Oftalmoloji, Cilt: 25 - Sayı: 0, 45–52. https://ajindex.com/articles/295430

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Kantarcı FA, Demirci G, Özsütçü M. Adenoviral Konjonktivit Görülen Hastaların Klinik ve Demografik Özelliklerinin Değerlendirilmesi. T Klin J Ophthalmol 2017;26(2):71-6
  2. Sundmacher R, Hillenkamp J, Reinhard T. Prospects for therapy and prevention of adenovirus keratocon- junctivitis. Ophthalmologe 2001;98:991-1007. American Academy of Ophthalmology. Conjunctivitis PPP-2013. 19 Şubat 2018 tarihinde https://www. aao.org/preferred-practice-pattern/conjunctivitis-ppp-- 2013 adresinden erişildi. Tatlipinar S. Akpek EK. Topical cyclosporin in the treatment of ocular surface disorders. Br J Opht hal - mol 2005;89:1363-1367.
  3. Okumus S, Coskun E, Tatar MG, Kaydu E, Yayuspayi R, Comez A, Erbagci I, Gurler B. Cyclosporine a 0.05% eye drops for the treatment of subepithelial in- filtrates after epidemic keratoconjunctivitis. BMC Ophthalmol 2012;12:42. Jeng BH, Holsclaw DS. Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after aden- oviral keratoconjunctivitis. Cornea 2011;30(9): 958- 61. Asena L, Şıngar Özdemir E, Burcu A, Ercan E, Çolak M, Altınörs DD. Comparison of clinical outcome with different treatment regimens in acute adenoviral kera- toconjunctivitis. Eye (Lond) 2017;31(5):781-7. Hossain P. Cyclosporine in ocular surface inflamma- tion. Eye (Lond) 2017;31(5):665-7.
  4. Ozturk HE, Sonmez B, Beden U. Corneal sensitivity may decrease in adenoviral epidemic keratoconjunc- tivitis-a confocal microscopic study. Eye Contact Lens 2013;39:264-8.
  5. Trinavarat A, Atchaneeyasakul LO. Treatment of epi- demic keratoconjunctivitis with 2% povidone-iodine: a pilot study. J Ocul Pharmacol Ther 2012;28(1):53-8.
  6. Clement C, Capriotti JA, Kumar M, Hobden JA, Foster TP, Bhattacharjee PS, Thompson HW, Mahmud R, Liang B, Hill JM. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone- iodine in a rabbit model of adenoviral keratoconjunc- tivitis. Invest Ophthalmol Vis Sci 2011;52(1):339-44.
  7. Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R. Topical treatment of acute aden- oviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol 2001;119(10):1487-91.
  8. Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clin- i